Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.

ABSTRACT:

Background

The National Comprehensive Cancer Network recommends either three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin (EPx4) as initial chemotherapy for the treatment of good-risk germ cell tumors (GCTs). To assess the response, toxicity, and survival outcomes of EPx4, we analyzed our experience.

Material and methods

Response and survival outcomes, selected toxicities, and adherence to chemotherapy dose and schedule were assessed in patients with good-risk GCT who received EPx4 at Memorial Sloan Kettering Cancer Center between 1982 and 2016. The results were compared with our past results and published data.

Results

Between 1982 and 2016, 944 patients with GCT were treated with EPx4, 289 who were previously reported plus

SUBMITTER: Funt SA 

PROVIDER: S-EPMC8176973 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature